News & Events Year None2019201820172016201520142013201220112009 06/11/19 REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference 05/30/19 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD 05/24/19 REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform 05/15/19 REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies 05/08/19 REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference 05/07/19 REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 04/30/19 REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
